137 related articles for article (PubMed ID: 15340558)
1. [Anti-SARS virus activities of different recombinant human interferons in cell culture system].
Duan ZJ; Zhang LL; Xie ZP; Yu ZA; Zhang LP; Zhang B; Liu YQ; Wang JW; Li WP; Zhang CH; Ma XJ; Shu YL; Duan SM; Li DX; Hou YD
Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi; 2003 Sep; 17(3):205-8. PubMed ID: 15340558
[TBL] [Abstract][Full Text] [Related]
2. Potent in vitro activity of the albumin fusion type 1 interferons (albumin-interferon-alpha and albumin-interferon-beta) against RNA viral agents of bioterrorism and the severe acute respiratory syndrome (SARS) virus.
Subramanian GM; Moore PA; Gowen BB; Olsen AL; Barnard DL; Paragas J; Hogan RJ; Sidwell RW
Chemotherapy; 2008; 54(3):176-80. PubMed ID: 18560223
[TBL] [Abstract][Full Text] [Related]
3. Interferon alfacon 1 inhibits SARS-CoV infection in human bronchial epithelial Calu-3 cells.
Kumaki Y; Day CW; Wandersee MK; Schow BP; Madsen JS; Grant D; Roth JP; Smee DF; Blatt LM; Barnard DL
Biochem Biophys Res Commun; 2008 Jun; 371(1):110-3. PubMed ID: 18406349
[TBL] [Abstract][Full Text] [Related]
4. In vitro inhibition of SARS virus replication by human interferons.
Dahl H; Linde A; Strannegård O
Scand J Infect Dis; 2004; 36(11-12):829-31. PubMed ID: 15764169
[TBL] [Abstract][Full Text] [Related]
5. Severe acute respiratory syndrome-related coronavirus is inhibited by interferon- alpha.
Ströher U; DiCaro A; Li Y; Strong JE; Aoki F; Plummer F; Jones SM; Feldmann H
J Infect Dis; 2004 Apr; 189(7):1164-7. PubMed ID: 15031783
[TBL] [Abstract][Full Text] [Related]
6. Interferon-beta 1a and SARS coronavirus replication.
Hensley LE; Fritz LE; Jahrling PB; Karp CL; Huggins JW; Geisbert TW
Emerg Infect Dis; 2004 Feb; 10(2):317-9. PubMed ID: 15030704
[TBL] [Abstract][Full Text] [Related]
7. Interferon alfacon1 is an inhibitor of SARS-corona virus in cell-based models.
Paragas J; Blatt LM; Hartmann C; Huggins JW; Endy TP
Antiviral Res; 2005 Jun; 66(2-3):99-102. PubMed ID: 15911026
[TBL] [Abstract][Full Text] [Related]
8. Treatment of SARS with human interferons.
Moriguchi H; Sato C
Lancet; 2003 Oct; 362(9390):1159. PubMed ID: 14550718
[No Abstract] [Full Text] [Related]
9. Comparison of an antiviral activity of recombinant consensus interferon with recombinant interferon-alpha-2b.
Koyama AH; Arakawa T; Adachi A
Microbes Infect; 1999 Nov; 1(13):1073-7. PubMed ID: 10572309
[TBL] [Abstract][Full Text] [Related]
10. SARS treatment. Interferon shows promise in monkeys.
Enserink M
Science; 2004 Feb; 303(5662):1273-5. PubMed ID: 14988528
[No Abstract] [Full Text] [Related]
11. Treatment of SARS with human interferons.
Cinatl J; Morgenstern B; Bauer G; Chandra P; Rabenau H; Doerr HW
Lancet; 2003 Jul; 362(9380):293-4. PubMed ID: 12892961
[TBL] [Abstract][Full Text] [Related]
12. [Development of the cDNA chip for SARS virus and a primary study on the possible molecular mechanism of interferon alpha2b inhibiting the SARS virus replication].
Shu YL; Duan ZJ; Wang Z; Sun MS; Zhang J; Zhang LL; Ma XJ; Peng JP; Jin Q; Hou YD
Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi; 2003 Sep; 17(3):209-12. PubMed ID: 15340559
[TBL] [Abstract][Full Text] [Related]
13. [A field trial of recombinant human interferon alpha-2b for nasal spray to prevent SARS and other respiratory viral infections].
Yu DX; Chen Q; Zhang LL; Liu Y; Yu ZA; Li ZF; Zhang LP; Hu GF; Duan ZJ; Chu XW; Zhang B; Yu SY; Hou YD
Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi; 2005 Sep; 19(3):216-9. PubMed ID: 16261200
[TBL] [Abstract][Full Text] [Related]
14. Treatment of SARS with human interferons.
Antonelli G; Scagnolari C; Vicenzi E; Clementi M
Lancet; 2003 Oct; 362(9390):1158; author reply 1158-9. PubMed ID: 14550714
[No Abstract] [Full Text] [Related]
15. Evaluation of immunomodulators, interferons and known in vitro SARS-coV inhibitors for inhibition of SARS-coV replication in BALB/c mice.
Barnard DL; Day CW; Bailey K; Heiner M; Montgomery R; Lauridsen L; Chan PK; Sidwell RW
Antivir Chem Chemother; 2006; 17(5):275-84. PubMed ID: 17176632
[TBL] [Abstract][Full Text] [Related]
16. In vitro susceptibility of 10 clinical isolates of SARS coronavirus to selected antiviral compounds.
Chen F; Chan KH; Jiang Y; Kao RY; Lu HT; Fan KW; Cheng VC; Tsui WH; Hung IF; Lee TS; Guan Y; Peiris JS; Yuen KY
J Clin Virol; 2004 Sep; 31(1):69-75. PubMed ID: 15288617
[TBL] [Abstract][Full Text] [Related]
17. Comparative susceptibility of respiratory viruses to recombinant interferons-alpha 2b and -beta.
Sperber SJ; Hayden FG
J Interferon Res; 1989 Jun; 9(3):285-93. PubMed ID: 2545792
[TBL] [Abstract][Full Text] [Related]
18. Current status of anti-SARS agents.
Shigeta S; Yamase T
Antivir Chem Chemother; 2005; 16(1):23-31. PubMed ID: 15739619
[TBL] [Abstract][Full Text] [Related]
19. Inhibition of SARS coronavirus infection in vitro with clinically approved antiviral drugs.
Tan EL; Ooi EE; Lin CY; Tan HC; Ling AE; Lim B; Stanton LW
Emerg Infect Dis; 2004 Apr; 10(4):581-6. PubMed ID: 15200845
[TBL] [Abstract][Full Text] [Related]
20. [Preventive and therapeutic effects of recombinant IFN-alpha2b nasal spray on SARS-CoV infection in Macaca mulata].
Gao H; Zhang LL; Wei Q; Duan ZJ; Tu XM; Yu ZA; Deng W; Zhang LP; Bao LL; Zhang B; Tong W; Hou YD; Zhang BL; Huang L; Qin C
Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi; 2005 Sep; 19(3):207-10. PubMed ID: 16261198
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
